Hemab Therapeutics (NASDAQ:COAG) Shares Gap Down – Time to Sell?

Hemab Therapeutics Holdings, Inc. (NASDAQ:COAG) shares gapped down before the market opened on Wednesday . The stock had previously closed at $25.44, but opened at $24.21. Hemab Therapeutics shares last traded at $25.03, with a volume of 50,300 shares trading hands.

Wall Street Analysts Forecast Growth

Separately, Wall Street Zen upgraded shares of Hemab Therapeutics to a “hold” rating in a report on Saturday, May 9th.

Hemab Therapeutics Trading Down 0.6%

Hemab Therapeutics (NASDAQ:COAG) last issued its quarterly earnings results on Thursday, May 21st. The company reported ($23.98) earnings per share (EPS) for the quarter.

Insider Transactions at Hemab Therapeutics

In other news, Director Ra Capital Management, L.P. purchased 2,675,000 shares of the firm’s stock in a transaction that occurred on Monday, May 4th. The stock was bought at an average price of $18.00 per share, for a total transaction of $48,150,000.00. Following the completion of the purchase, the director directly owned 6,149,096 shares of the company’s stock, valued at $110,683,728. The trade was a 77.00% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Insiders have purchased a total of 2,902,872 shares of company stock valued at $53,769,784 in the last ninety days.

About Hemab Therapeutics

Hemab Therapeutics is a clinical-stage biotechnology company focused on developing novel therapies for people with serious bleeding and thrombotic disorders. The company’s research is centered on treatments designed to address diseases of the blood and coagulation system, with the goal of improving outcomes for patients who may not be adequately served by existing options.

Hemab’s pipeline includes drug candidates aimed at rare hematologic conditions, including factor XI-related approaches and other programs in inherited bleeding disorders.